attentin 20 mg tablett
medice arzneimittel pütter gmbh & co. kg - dexamfetaminsulfat - tablett - 20 mg - isomalt hjälpämne; dexamfetaminsulfat 20 mg aktiv substans
attentin 10 mg tablett
medice arzneimittel pütter gmbh & co. kg - dexamfetaminsulfat - tablett - 10 mg - isomalt hjälpämne; dexamfetaminsulfat 10 mg aktiv substans
acetylsalicylsyra aristo 100 mg enterotablett
aristo pharma gmbh - acetylsalicylsyra - enterotablett - 100 mg - acetylsalicylsyra 100 mg aktiv substans; laktosmonohydrat hjälpämne
acetylsalicylsyra aristo 75 mg enterotablett
aristo pharma gmbh - acetylsalicylsyra - enterotablett - 75 mg - acetylsalicylsyra 75 mg aktiv substans; laktosmonohydrat hjälpämne; para-orange aluminiumlack hjälpämne
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ögonsjukdomar - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
oxycodone/naloxone glenmark 10 mg/5 mg depottablett
glenmark arzneimittel gmbh - naloxonhydrokloriddihydrat; oxikodonhydroklorid - depottablett - 10 mg/5 mg - laktosmonohydrat hjälpämne; stearylalkohol hjälpämne; naloxonhydrokloriddihydrat 5,5 mg aktiv substans; oxikodonhydroklorid 10 mg aktiv substans
oxycodone/naloxone glenmark 5 mg/2,5 mg depottablett
glenmark arzneimittel gmbh - naloxonhydrokloriddihydrat; oxikodonhydroklorid - depottablett - 5 mg/2,5 mg - laktosmonohydrat hjälpämne; stearylalkohol hjälpämne; naloxonhydrokloriddihydrat 2,75 mg aktiv substans; oxikodonhydroklorid 5 mg aktiv substans
oxycodone/naloxone glenmark 20 mg/10 mg depottablett
glenmark arzneimittel gmbh - naloxonhydrokloriddihydrat; oxikodonhydroklorid - depottablett - 20 mg/10 mg - stearylalkohol hjälpämne; oxikodonhydroklorid 20 mg aktiv substans; naloxonhydrokloriddihydrat 11 mg aktiv substans
oxycodone/naloxone glenmark 40 mg/20 mg depottablett
glenmark arzneimittel gmbh - naloxonhydrokloriddihydrat; oxikodonhydroklorid - depottablett - 40 mg/20 mg - stearylalkohol hjälpämne; naloxonhydrokloriddihydrat 22 mg aktiv substans; oxikodonhydroklorid 40 mg aktiv substans
adakveo
novartis europharm limited - crizanlizumab - anemi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.